Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Tabletop particle accelerator could transform medicine and materials science 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Add as a preferred source on Google
Many companies are already undergoing trials for a possible cure to the ongoing COVID-19 pandemic. Aside from the developments made by Pfizer and Moderna in developing their respective vaccines, another pharmaceutical company has made progress.
UK pharmaceutical firm AstraZeneca has developed a COVID-19 antibody cocktail that can potentially protect the person from infection for up to 12 months. The drug, known as AZD7442, makes use of a different process in helping the body fight the virus compared to a regular vaccine. Late-stage trials of the drug are already underway and the firm has started recruiting international clinical trials involving 5,000 from both Europe and the United States.
AZD7442 relies on the prophylactic process which involves introducing new antibodies into the body to fight the disease instead of triggering the body to create them. The drug acts with monoclonal antibodies that mimic the body’s natural antibodies and this process has already been used to treat cancer patients. This will especially be beneficial for those with weak immune systems compared to simply being vaccines as their bodies have already been compromised from creating new antibodies. The trials began over the weekend in the UK, involving 1,000 participants in nine sites.
The firm announced that this antibody cocktail can potentially treat patients or be taken as a preventative medication especially to healthcare workers at the front lines. “These have been engineered specifically to have what we call a long half-life, so we think they can confer protection for at least six, but more likely closer to 12 months,” said the company’s executive vice president of biopharmaceuticals research and development Mene Pangalos.
As the world waits for vaccines and a cure for COVID-19, people are highly advised to adhere to public health and safety guidelines to slow the spread of the coronavirus. Video streaming platform YouTube recently clamped down on the right-wing media organization OANN from posting videos and live streaming for a week, after the organization shared a fake cure for the disease.
Aside from restricting uploads, YouTube has also demonetized the channel, citing that the OANN has repeatedly violated its misinformation guidelines especially related to COVID-19.
